eMedicine Specialties > Emergency Medicine > Toxicology

Withdrawal Syndromes: Differential Diagnoses & Workup

Author: Nathanael J McKeown, DO, Assistant Professor, Oregon Health and Science University; Medical Toxicologist, Oregon Poison Center; Attending Physician, Emergency Medicine, Portland Veteran Affairs Medical Center, Oregon Health and Science University
Coauthor(s): Patrick L West, MD, Clinical Instructor, Medical Toxicology Fellow, Department of Emergency Medicine, Oregon Health and Sciences University; Staff Physician, Department of Emergency Medicine, Portland Veterans Affairs Medical Center
Contributor Information and Disclosures

Updated: Oct 27, 2009

Differential Diagnoses

Acute Coronary Syndromes
Hypophosphatemia
Addison Disease
Pancreatitis
Adrenal Crisis
Panic Disorders
Alcohol and Substance Abuse Evaluation
Status Epilepticus
Alcoholic Ketoacidosis
Toxicity, Amphetamine
Anxiety
Toxicity, Anticholinergic
CNS disorders
Toxicity, Cocaine
Delirium Tremens
Toxicity, Hallucinogen
Delirium, Dementia, and Amnesia
Toxicity, MDMA
Depression and Suicide
Toxicity, Phencyclidine
Diabetic Ketoacidosis
Toxicity, Salicylate
Hyperthyroidism, Thyroid Storm, and Graves Disease
Toxicity, Sympathomimetic
Hyperventilation Syndrome
Toxicity, Thyroid Hormone
Hypoglycemia
Wernicke Encephalopathy
Hypomagnesemia

Workup

Laboratory Studies

  • Serum glucose or finger-stick glucose test is indicated.
    • Patients with liver disease due to alcoholism have reduced glycogen stores, and ethanol impairs gluconeogenesis. As a consequence, these patients are susceptible to hypoglycemia.
    • Patients in alcohol withdrawal develop anxiety, agitation, tremor, seizure, and diaphoresis, all of which can occur with hypoglycemia.
  • Analysis of arterial blood gases may be indicated.
    • Mixed acid-base disorders are common and usually result from AKA, volume-contraction alkalosis, and respiratory alkalosis.
    • Patients with these disorders may have hypoxia due to aspiration pneumonitis.
  • Chemistry panel analysis is indicated.
    • A CHEM-7 analysis or its equivalent is indicated to look for acidosis, dehydration, concurrent renal disease, and other abnormalities that can occur in patients with chronic alcoholism. It also provides data needed to calculate anion and delta gaps, which are helpful in differentiating mixed acid-base disorders.
    • A low BUN value is expected in alcoholic liver disease. Obtain lipase levels if pancreatitis is suspected. Obtain the blood ammonia level if hepatic encephalopathy is suspected.
    • Determination of magnesium and calcium levels and liver function tests (LFTs) may be indicated because patients with chronic alcoholism usually have dietary magnesium deficiency and possibly concurrent alcoholic hepatitis. Alcoholic pancreatitis may cause hypocalcemia.
  • Urinalysis is indicated.
    • Routinely check for ketones, as patients may have associated AKA.
    • Ketonuria without glycosuria must be investigated further to exclude AKA and the ingestion of isopropyl alcohol.
    • Myoglobinuria from rhabdomyolysis may first be suspected when hematuria is noted on urinalysis.
  • CBC determination is recommended.
    • Long-term alcohol ingestion leads to myelosuppression with a slight reduction in all cell lines. Thrombocytopenia is common.
    • Blood loss from the GI tract and nutritional deficiencies producing anemia are common in alcohol withdrawal.
    • Many patients have dehydration, and hemoconcentration and anemia may become apparent only when rehydration is accomplished.
    • Megaloblastic anemia is observed in people with alcoholism and based on a dietary deficiency of vitamin B-12 and folate. Increased mean corpuscular volume suggests this condition.
  • Cardiac markers may be indicated.
    • Elevated CK and cardiac troponin levels may indicate myocardial infarction resulting from increased demands placed on the heart from hypertension associated with alcohol withdrawal or from hypertension produced by cocaine intoxication prior to the patient's presentation.
    • Elevated CK level can also be from rhabdomyolysis, which may be associated with significant adrenergic hyperactivity from alcohol withdrawal or from myonecrosis in immobile patients.
  • Measurement of prothrombin time may be indicated.
    • The prothrombin time (PT) is a useful index of liver function; patients with cirrhosis are at risk for coagulopathy.
    • PT should be considered in a patient with active bleeding in the GI tract or CNS.
  • Toxicology screening may be indicated.
    • Consider measuring serum osmolality and screening for toxic alcohols if the patient is severely acidemic.
    • The ethanol concentration is frequently zero. However, some patients that are habituated to alcohol can be in severe alcohol withdrawal even if ethanol levels are clinically significant.
    • Send urine samples for drug toxicology screening because co-ingestion of other medications (eg, psychiatric medications) and use of other recreational drugs are common.
    • GHB, ketamine, fentanyl, and many other drugs of abuse are not included in routine urine drug screening, and a special request may be required if use of these drugs is suspected.

Imaging Studies

Imaging studies should be directed to the patient's clinical course.

  • Chest radiography
    • Aspiration pneumonia is common among patients with alcohol withdrawal syndrome.
    • People with chronic alcoholism may have cardiomyopathy and CHF.
    • Patients using intravenous drugs are at increased risk for immunosuppression and consequently prone to pneumonia.
  • Head CT scanning
    • Patients with alcohol withdrawal syndrome are at risk for intracranial bleeding because of cortical atrophy and coagulopathy.
    • Consider obtaining a head CT in patients with an inappropriate level of consciousness, in those with multiple seizures, in those with signs of head trauma, and in those with an unexpected failure to respond to treatment.
    • Cocaine can cause intracerebral bleeding due to hypertension. The symptoms may closely resemble those of the cocaine wash-out syndrome.
  • Abdominal CT scanning: Patients with a history of intravenous drug abuse and unexplained hip pain may have intra-abdominal pathology, including psoas abscess, which may be seen on abdominal CT scan or ultrasonography.
  • Spinal MRI: In patients with unexplained back pain, intravenous drug abuse, and fever, spinal MRI may be required to rule out epidural abscess, particularly if focal neurologic deficits are also present.
  • Other imaging may be indicated if trauma or other associated conditions are suspected.

Other Tests

  • Electrocardiography
    • Adrenergic storm produced by alcohol withdrawal increases demands on the heart and may precipitate infarction in susceptible individuals.
    • A prolonged QTc interval has been described in patients with alcohol withdrawal syndrome.4 The interval gradually reverts to normal as withdrawal symptoms remit.
  • Lumbar puncture: One should have a low threshold for lumbar puncture and spinal-fluid analysis to rule out meningitis or subarachnoid hemorrhage because individuals in withdrawal are at increased risk.
  • Blood cultures may also be indicated if sepsis or endocarditis is suspected in this group of often immunosuppressed patients.
  • Additional tests may be indicated based on a patient's presentation.

More on Withdrawal Syndromes

Overview: Withdrawal Syndromes
Differential Diagnoses & Workup: Withdrawal Syndromes
Treatment & Medication: Withdrawal Syndromes
Follow-up: Withdrawal Syndromes
Multimedia: Withdrawal Syndromes
References

References

  1. Nagy J. Alcohol Related Changes in Regulation of NMDA Receptor Functions. Curr Neuropharmacol. Mar 2008;6(1):39-54. [Medline].

  2. Tarabar AF, Nelson LS. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol Rev. 2004;23(1):45-9. [Medline].

  3. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM. Jan 2008;10(1):69-74. [Medline].

  4. Otero-Antón E, González-Quintela A, Saborido J, Torre JA, Virgós A, Barrio E. Prolongation of the QTc interval during alcohol withdrawal syndrome. Acta Cardiol. 1997;52(3):285-94. [Medline].

  5. Fisher CM. Prompt responses to the administration of ethanol in the treatment of the alcohol withdrawal syndrome (AWS). Neurologist. Sep 2009;15(5):242-4. [Medline].

  6. Hack JB, Hoffmann RS, Nelson LS. Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early?. J Med Toxicol. Jun 2006;2(2):55-60. [Medline].

  7. Hayner CE, Wuestefeld NL, Bolton PJ. Phenobarbital treatment in a patient with resistant alcohol withdrawal syndrome. Pharmacotherapy. Jul 2009;29(7):875-8. [Medline].

  8. Subramaniam K, Gowda RM, Jani K, et al. Propofol combined with lorazepam for severe poly substance misuse and withdrawal states in intensive care unit: a case series and review. Emerg Med J. Sep 2004;21(5):632-4. [Medline][Full Text].

  9. Kahkonen S, Bondarenko B, Lipsanen J, et al. Cardiovascular effects of propranolol in patients with alcohol dependence during withdrawal. Int J Psychophysiol. Dec 2007;66(3):225-30. [Medline].

  10. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care. 2008;8(3):430-3. [Medline].

  11. [Best Evidence] Weinberg JA, Magnotti LJ, Fischer PE, et al. Comparison of intravenous ethanol versus diazepam for alcohol withdrawal prophylaxis in the trauma ICU: results of a randomized trial. J Trauma. Jan 2008;64(1):99-104. [Medline].

  12. Bayard M, McIntyre J, Hill KR, et al. Alcohol withdrawal syndrome. Am Fam Physician. Mar 15 2004;69(6):1443-50. [Medline][Full Text].

  13. DeBellis R, Smith BS, Choi S, et al. Management of delirium tremens. J Intensive Care Med. May-Jun 2005;20(3):164-73. [Medline].

  14. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ. Mar 9 1999;160(5):649-55. [Medline][Full Text].

  15. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. May 1 2003;348(18):1786-95. [Medline].

  16. Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. Jul 12 2004;164(13):1405-12. [Medline].

  17. McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med. Jun 2000;28(6):1781-4. [Medline].

  18. Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. Jan-Feb 2002;37(1):67-73. [Medline][Full Text].

  19. Olmedo R, Hoffman RS. Withdrawal syndromes. Emerg Med Clin North Am. May 2000;18(2):273-88. [Medline].

  20. Reoux JP, Miller K. Routine hospital alcohol detoxification practice compared to symptom triggered management with an Objective Withdrawal Scale (CIWA-Ar). Am J Addict. Spring 2000;9(2):135-44. [Medline].

  21. Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. Nov 1989;84(11):1353-7. [Medline].

Further Reading

Keywords

withdrawal syndrome, drug withdrawal, alcohol withdrawal, alcoholism, alcohol tolerance, alcohol-withdrawal syndrome, alcohol withdrawal syndrome, AWS, drug abuse, drug tolerance, intravenous drug abuse, IV drug abuse, IVDA, opiate abuse, opiate withdrawal

Contributor Information and Disclosures

Author

Nathanael J McKeown, DO, Assistant Professor, Oregon Health and Science University; Medical Toxicologist, Oregon Poison Center; Attending Physician, Emergency Medicine, Portland Veteran Affairs Medical Center, Oregon Health and Science University
Nathanael J McKeown, DO is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, Society for Academic Emergency Medicine, and Wilderness Medical Society
Disclosure: Nothing to disclose.

Coauthor(s)

Patrick L West, MD, Clinical Instructor, Medical Toxicology Fellow, Department of Emergency Medicine, Oregon Health and Sciences University; Staff Physician, Department of Emergency Medicine, Portland Veterans Affairs Medical Center
Disclosure: Nothing to disclose.

Medical Editor

Theodore J Gaeta, DO, MPH, FACEP, Clinical Associate Professor, Department of Emergency Medicine, Joan and Sanford Weill Medical College at Cornell University; Vice Chairman and Program Director of Emergency Medicine Residency Program, Department of Emergency Medicine, New York Methodist Hospital; Academic Chair, Adjunct Professor, Department of Emergency Medicine, St George's University School of Medicine
Theodore J Gaeta, DO, MPH, FACEP is a member of the following medical societies: Alliance for Clinical Education, American College of Emergency Physicians, Clerkship Directors in Emergency Medicine, Council of Emergency Medicine Residency Directors, New York Academy of Medicine, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

John T VanDeVoort, PharmD, Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals
John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists
Disclosure: Nothing to disclose.

Managing Editor

Michael J Burns, MD, Instructor, Department of Emergency Medicine, Harvard University Medical School, Beth Israel Deaconess Medical Center
Michael J Burns, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD, Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.